The U.S. Food and Drug Administration (FDA) granted initial approval for the Lecanemab Autoinjector (lecanemab-irmb) on August 29, 2025. This approval introduces a new administration option for the drug lecanemab.
Background
This approval specifically pertains to an autoinjector formulation of lecanemab, offering an alternative delivery method for the medication. The sponsor for this approval is EISAI INC.
What this means
The FDA's approval of the Lecanemab Autoinjector provides clinicians and patients with an additional method for administering lecanemab. This new formulation could potentially enhance convenience and accessibility for individuals receiving treatment, offering more flexibility in how the medication is delivered.
Source
This information is based on an initial approval by the U.S. Food and Drug Administration (FDA) for Biologics License Application (BLA) 761375. The approval was granted on August 29, 2025, and details are available on accessdata.fda.gov.